Does Centene Corporation Cover Metformin?

What Is Centene Corporation and Which Plans Does It Run?

Centene Corporation is one of the largest managed-care organizations in the United States, serving more than 28 million members across Medicaid, Medicare Advantage, the ACA Marketplace, and TRICARE. Its subsidiary brands include Ambetter (ACA Marketplace), WellCare (Medicare Advantage and Medicaid), Health Net (California and Arizona), Peach State Health Management (Georgia Medicaid), Sunshine Health (Florida Medicaid), and roughly two dozen other state-specific entities.

Because each subsidiary files its own formulary with CMS or state Medicaid agencies, coverage details vary slightly by brand, state, and plan year. The shared pharmacy benefit management infrastructure, however, means that metformin's placement as a preferred generic is consistent across the network.

How Centene Structures Its Drug Formularies

Centene subsidiaries typically use a five-tier formulary structure:

• Tier 1: Preferred generic drugs (lowest cost-sharing)
• Tier 2: Non-preferred generic drugs
• Tier 3: Preferred brand drugs
• Tier 4: Non-preferred brand drugs
• Tier 5: Specialty drugs

Generic metformin hydrochloride immediate-release (IR) and extended-release (ER) tablets land on Tier 1 for the vast majority of Centene plans. Brand-name Glucophage is no longer widely marketed; if a prescriber requests the brand by name, it may fall on Tier 3 with significantly higher cost-sharing.

Why Metformin Is So Consistently Covered

Metformin received FDA approval for type 2 diabetes management in 1994, and generic versions entered the market in force after 2002 [1]. Because the drug has been off-patent for more than two decades, its acquisition cost for insurers is extremely low, often below $4 per 30-day supply at the wholesale level. The American Diabetes Association's 2024 Standards of Care list metformin as the preferred initial pharmacologic agent for type 2 diabetes in most adults [2]. That guideline status gives payers a strong clinical and actuarial reason to keep the drug on Tier 1 without barriers.

Metformin Coverage on Ambetter Plans (ACA Marketplace)

Ambetter is Centene's ACA Marketplace brand, operating in more than 25 states. On the 2024 and 2025 Ambetter plan formularies, generic metformin IR (500 mg, 850 mg, and 1,000 mg tablets) and metformin ER (500 mg, 750 mg, and 1,000 mg tablets) are listed as Tier 1 preferred generics with no prior-authorization requirement and no step-therapy restriction.

Cost-Sharing Details by Metal Level

Member out-of-pocket costs depend on the metal tier selected at enrollment:

• Bronze: $0 to $3 per 30-day fill before deductible (many Bronze plans exempt generic Tier 1 drugs from the deductible entirely)
• Silver: $0 to $5 per 30-day fill; Cost-Sharing Reduction (CSR) variants can reduce this further
• Gold: $0 per 30-day fill on most Gold formularies
• Platinum: $0 per 30-day fill

Members who receive a Cost-Sharing Reduction subsidy (available when household income falls between 100% and 250% of the federal poverty level and the member enrolls in a Silver plan) often pay nothing for Tier 1 generics. The ACA's cost-sharing reduction framework is codified under 45 CFR Part 156 and reviewed annually by CMS [3].

Accessing Metformin Through Ambetter's Preferred Pharmacy Network

Ambetter plans designate preferred retail pharmacies, typically large chains such as CVS, Walgreens, Walmart Pharmacy, and Kroger Health, where Tier 1 copays apply. Using a non-preferred pharmacy may increase the copay by $5 to $15. Mail-order programs through Centene's pharmacy benefit manager often allow a 90-day supply at two times the 30-day copay, effectively providing one month free.

Metformin Coverage on WellCare Plans (Medicare Advantage and Medicaid)

WellCare operates Medicare Advantage (MA) plans in more than 30 states and manages Medicaid contracts in several states. Metformin coverage differs slightly between these two program types.

WellCare Medicare Advantage

Under Medicare Part D, which governs drug coverage within Medicare Advantage plans, all Part D formularies must cover drugs in the "protected classes," and while diabetes medications are not technically a protected class, CMS requires that plans cover "all or substantially all" drugs in six protected categories and provide "access to needed drugs" in other therapeutic classes. The 2024 CMS Medicare Prescription Drug Benefit Manual specifies that plan formularies must meet CMS approval, and generic metformin consistently passes that review [4].

On WellCare's 2024 and 2025 MA formularies, generic metformin IR and ER sit at Tier 1 with a $0 copay during both the Initial Coverage Stage and, for most plans, the Catastrophic Stage. The Medicare Part D Low-Income Subsidy (LIS), also called Extra Help, further reduces or eliminates cost-sharing for eligible members. Roughly 13 million Medicare beneficiaries qualify for Extra Help based on 2023 CMS enrollment data [5].

WellCare Medicaid

Medicaid programs cover metformin at no cost to the member in nearly all states, because federal Medicaid law (42 U.S.C. § 1396r-8) requires states to cover FDA-approved drugs from manufacturers that have signed rebate agreements, and virtually all generic metformin manufacturers participate in the Medicaid Drug Rebate Program [6]. WellCare's Medicaid managed-care contracts in Georgia, Florida, Kentucky, and other states list metformin on their preferred drug lists (PDL) with a $0 copay.

Metformin Coverage on Health Net Plans (California and Arizona)

Health Net, Centene's California-focused subsidiary, offers Covered California (ACA Marketplace) plans, Medi-Cal managed care, and commercial group plans. On all three product lines, generic metformin is Tier 1 with no PA requirement.

Medi-Cal Formulary Rules

California's Medi-Cal program uses a statewide PDL administered by the California Department of Health Care Services (DHCS). Metformin IR and ER are on the Medi-Cal PDL as preferred agents for type 2 diabetes, meaning Health Net's Medi-Cal contracts must cover them with $0 member cost-sharing [7]. California Medi-Cal members pay no copay for any PDL drug.

Covered California Plans

On Health Net's 2025 Covered California Silver 70 plan, generic metformin is listed as a Tier 1 generic with a $5 copay per 30-day supply before the deductible and $0 after. Bronze plans exempt Tier 1 generics from the deductible under the ACA's minimum value standard, which CMS defines in 45 CFR § 156.130 [3].

Does Metformin Require Prior Authorization Under Centene Plans?

No. Standard generic metformin IR and ER do not require prior authorization on any major Centene subsidiary formulary reviewed for this article. Prior authorization is a process insurers use to require clinician-submitted documentation before approving a drug. Because metformin is a first-line, inexpensive generic with a decades-long safety record, Centene and its subsidiaries have no actuarial reason to impose that barrier.

When Step Therapy Could Apply

Some Centene employer-sponsored commercial plans (sold to large companies that self-fund their benefits) may include step-therapy language for diabetes drugs, meaning the plan prefers metformin as a required first step before covering more expensive agents such as GLP-1 receptor agonists (semaglutide, tirzepatide) or SGLT-2 inhibitors (empagliflozin, dapagliflozin). That step-therapy requirement benefits, not harms, metformin coverage. The member must try metformin first, which means it is covered without restriction.

Quantity Limits

Centene formularies typically allow up to a 30-day supply at retail (or 90-day at mail order) without quantity limits for metformin at standard doses. The maximum approved dose of metformin IR is 2,550 mg per day; ER is 2,000 mg per day per FDA labeling [1]. Prescriptions within those dose ranges are dispensed without issue.

Metformin's Clinical Profile: Why Physicians Prescribe It So Frequently

Understanding why metformin is covered so broadly requires understanding its clinical standing. Metformin works primarily by reducing hepatic glucose production and improving peripheral insulin sensitivity without causing hypoglycemia or significant weight gain at standard doses [8].

Efficacy Data From Key Trials

The United Kingdom Prospective Diabetes Study (UKPDS 34, N=1,704) showed that metformin reduced the risk of any diabetes-related endpoint by 32% compared to conventional dietary therapy in overweight patients with type 2 diabetes (P<0.001), with a 36% reduction in all-cause mortality [9]. These landmark findings, published in The Lancet in 1998, established metformin as the anchor drug for type 2 diabetes pharmacotherapy.

The Diabetes Prevention Program (DPP, N=3,234) found that metformin 850 mg twice daily reduced the incidence of type 2 diabetes by 31% compared to placebo over an average follow-up of 2.8 years [10]. This trial established metformin's role in diabetes prevention, an off-label use that many Centene plans also cover when the prescriber documents prediabetes.

Off-Label Uses That May Affect Coverage

Metformin is prescribed off-label for polycystic ovary syndrome (PCOS), where a 2017 Cochrane review (52 trials, N=4,803) found it improved menstrual frequency and reduced androgen levels compared to placebo [11]. It is also under active investigation for longevity and aging, with the TAME (Targeting Aging with Metformin) trial, funded by the American Federation for Aging Research and currently enrolling approximately 3,000 adults aged 65 to 79, testing whether metformin delays age-related diseases and extends healthspan [12].

Off-label prescriptions may face more scrutiny on Centene plans. A prescriber requesting metformin for PCOS or longevity may need to include a clinical note indicating the indication, though PA is still rarely required given the drug's low cost.

The table below summarizes how Centene's major subsidiaries handle metformin coverage across indications:

| Subsidiary | Plan Type | Tier | PA Required | Member Cost (Tier 1) | |---|---|---|---|---| | Ambetter | ACA Marketplace | 1 | No | $0 to $5 | | WellCare | Medicare Advantage | 1 | No | $0 | | WellCare | Medicaid | PDL | No | $0 | | Health Net | Medi-Cal | PDL | No | $0 | | Health Net | Covered California | 1 | No | $0 to $5 | | Sunshine Health | Florida Medicaid | PDL | No | $0 | | Peach State | Georgia Medicaid | PDL | No | $0 |

How to Verify Your Specific Centene Plan Covers Metformin

Formularies change annually. CMS requires Medicare Part D plans to publish updated formularies by October 1 of each plan year, and ACA Marketplace plans must finalize formularies before open enrollment begins in November [4]. To confirm coverage for your specific plan and plan year:

Step 1: Use the Plan's Online Formulary Tool

Every Centene subsidiary maintains a drug lookup tool on its member portal. Enter "metformin" and your plan name to confirm the tier and any restrictions. Ambetter's tool is at ambetterhealth.com; WellCare's is at wellcare.com.

Step 2: Call Member Services

The phone number on the back of your insurance card connects to a pharmacy benefit specialist who can confirm the exact copay, quantity limit, and any PA requirements for your plan and your specific metformin formulation (IR vs. ER, dose, manufacturer).

Step 3: Ask Your Pharmacist

Retail pharmacists can run a test claim through your Centene plan before you arrive at the pickup window. This "point-of-sale" inquiry takes about 90 seconds and tells the pharmacist your exact copay and any coverage edits in real time.

Step 4: Request an Exception If Coverage Is Denied

If, for any reason, a Centene plan denies coverage for metformin, you have the right to request a formulary exception. The ADA's 2024 Standards of Care state that "insulin and other antihyperglycemic agents should be covered by all health plans" [2], and metformin is specifically named as first-line therapy. A physician-submitted exception letter citing that guideline has a high probability of approval.

Reducing Your Cost Further: Programs That Work Alongside Centene Coverage

Even with Tier 1 coverage, some members look to reduce their cost to absolute zero.

GoodRx and Cash-Pay Pricing

At major pharmacy chains, a 30-day supply of generic metformin IR 500 mg (60 tablets) costs between $4 and $9 without insurance using GoodRx or similar discount cards. In some cases, paying cash through a discount program is cheaper than running your Centene plan if your plan has a deductible that has not yet been met. GoodRx coupons cannot be combined with insurance at the same transaction, so compare both prices before checkout.

Manufacturer Assistance

Because metformin is generic, branded manufacturer coupons do not apply. However, Centene's Medicaid members who have $0 cost-sharing already face no financial barrier.

Walmart's $4 Generic Program

Walmart Pharmacy offers a 30-day supply of metformin IR (up to 1,000 mg per day) for $4 without any insurance card. This price is competitive with or lower than most Tier 1 copays and is useful if a member is between coverage periods.

Safety Profile and Monitoring Requirements

Metformin's safety record is well established over more than 60 years of global use. The most clinically significant concern is metformin-associated lactic acidosis (MALA), which the FDA estimates occurs in approximately 0.03 cases per 1,000 patient-years and is almost exclusively associated with contraindicated use in patients with an eGFR <30 mL/min/1.73m² [1].

eGFR Thresholds for Prescribing

The FDA updated metformin's labeling in 2016 to replace the absolute serum creatinine contraindication with an eGFR-based threshold [1]:

• eGFR >45: Safe to initiate and continue
• eGFR 30 to 45: Continue with caution; do not initiate
• eGFR <30: Contraindicated

Centene plans cover the basic metabolic panel (BMP) or comprehensive metabolic panel (CMP) used to calculate eGFR as a preventive benefit under ACA Section 2713, which requires coverage of USPSTF Grade A and B services without cost-sharing [3].

Vitamin B12 Monitoring

Long-term metformin use is associated with vitamin B12 malabsorption. The ADA recommends periodic B12 measurement in patients on long-term metformin, particularly those with peripheral neuropathy or anemia [2]. A 2019 systematic review (N=7,947) found that metformin reduced serum B12 by a mean of 57 pmol/L compared to placebo (P<0.001) [13]. Centene plans cover the serum B12 test under standard laboratory benefits, typically at $0 after deductible for in-network labs.

Metformin in the Context of Longevity Medicine

Metformin has attracted intense interest from longevity researchers because of its effects on AMP-activated protein kinase (AMPK), mTOR signaling, and IGF-1 pathways that are mechanistically linked to cellular aging [14]. Observational data from a 2014 study in Diabetes, Obesity and Metabolism (N=78,241 type 2 diabetes patients on metformin monotherapy vs. N=12,658 non-diabetic controls) found that metformin-treated patients survived longer than matched non-diabetic controls over a median 4.0-year follow-up period [15].

The TAME trial, currently enrolling at 14 academic centers across the United States, will provide the first randomized controlled evidence on whether metformin extends healthspan in non-diabetic older adults [12]. Results are expected around 2028.

For Centene members pursuing metformin for longevity rather than a diagnosed metabolic condition, coverage is less certain. A physician who documents a recognized indication (type 2 diabetes, prediabetes, PCOS, or metabolic syndrome) is more likely to see the prescription covered without dispute.